

**14 OCTOBER 2020**

# LITTLE GREEN PHARMA GRANTED GMP LICENCE

**ASX ANNOUNCEMENT**

## Highlights:


- 🌿 Little Green Pharma granted Therapeutic Goods Administration (TGA) Good Manufacturing Practices (GMP) licence for recently commissioned manufacturing facility
- 🌿 LGP only fully-TGA and Office of Drug Control (ODC) licenced and permitted medicinal cannabis company listed on ASX
- 🌿 LGP now sole ASX-listed medicinal cannabis company with inhouse capability to manufacture TGA GMP-grade medicinal cannabis flower and oil products from own cultivated flower for delivery into Australian and higher-margin European markets

**Little Green Pharma Ltd (ASX: LGP, “LGP” or the “Company”)** is pleased to announce the grant of a Good Manufacturing Practices licence by the TGA over the Company’s recently commissioned manufacturing facility in Western Australia.

### Licencing and authorisations

The GMP licencing of the Company’s manufacturing facility is the culmination of a two-year regulatory strategy. LGP now holds over 20 State and Federal operating authorisations, allowing it to operate a fully in-house and vertically-integrated cannabis cultivation, production, manufacturing, and wholesaling supply chain, capable of supplying various LGP-branded medicinal cannabis products into Australian and international markets.

The Company’s broad suite of licences and authorisations gives it the flexibility to respond to changing market conditions, focus on higher-margin aspects of the product supply chain, and react quickly to new market opportunities.





## Commenting on the grant, LGP Managing Director Fleta Solomon said:

*“The grant represents the culmination of LGP’s long-term regulatory strategy and is a clear watershed moment for the Company. The grant of this GMP licence differentiates the Company as the only fully TGA and ODC licensed and permitted medicinal cannabis company listed on the ASX with local Australian cultivation, manufacturing and wholesaling capacity, as well as brands in market. This end-to-end capability allows us to more effectively manage costs, focus on higher-margin aspects of the supply chain, and supply LGP-branded GMP-grade medicinal cannabis products into the highly regulated markets of the European Union.”*

### Access to European medicinal cannabis markets

LGP is also now the only ASX-listed medicinal cannabis company able to deliver higher-margin, TGA GMP-dried and processed medicinal cannabis flower and oil medicines into European markets, including Germany. Germany is the third largest medicinal cannabis market globally and is also currently wholly dependent on imports of medicinal cannabis products, with more than half of the market value derived from medicinal cannabis flower.<sup>1</sup> Currently, only a handful of international manufacturers supply medicinal cannabis medicines into Germany.

### GMP-licenced manufacturing facility

Operating an in-house manufacturing capability avoids potential future congestion and competition for outsourced Australian manufacturing capacity and allows LGP to focus on de-bottlenecking and identifying further manufacturing cost efficiencies. It will also facilitate expedited inspection and auditing by offshore distributors.

LGP plans to develop its capability to manufacture additional GMP-licenced cannabis products and other pharmaceutical formulations, and potentially offer toll extraction and manufacturing services to other producers.

The manufacturing facility was constructed with funding support from the West Australian Government and represents a regional manufacturing success story for South West Western Australia.

<sup>1</sup> <https://www.healtheuropa.eu/exploring-growth-in-the-european-medical-cannabis-market/100849/>

ENDS

BY ORDER OF THE BOARD

A handwritten signature in dark ink, appearing to read "Alistair Warren", written over a horizontal line.

**Alistair Warren**  
Company Secretary





---

**For further information please contact:**

**Alistair Warren**  
**Company Secretary**  
Little Green Pharma  
**E: [alistair@lgpharma.com.au](mailto:alistair@lgpharma.com.au)**  
**M: +61 8 6280 0050**

**Fleta Solomon**  
**Managing Director**  
Little Green Pharma  
**E: [fleta@lgpharma.com.au](mailto:fleta@lgpharma.com.au)**  
**M: +41 782 260 200**

---

**About Little Green Pharma**

Little Green Pharma is the only ASX-listed vertically integrated medicinal cannabis business with operations from cultivation and production through to manufacturing and distribution.

The Company has an indoor cultivation facility and manufacturing facility in Western Australia for the production of its own-branded range of GMP-grade medicinal cannabis products.

Little Green Pharma products comply with all required Therapeutic Goods Administration regulations and testing requirements. With a growing range of products containing differing ratios of active ingredients, Little Green Pharma supplies medical-grade cannabis products to Australian and overseas markets.

The Company has a strong focus on patient access in the emerging global medicinal cannabis market and is actively engaged in promoting education and outreach programs, as well as participating in clinical investigations and research projects to develop innovative new delivery systems.

For more information about Little Green Pharma go to: [www.littlegreenpharma.com](http://www.littlegreenpharma.com)

**Help us be Green**

LGP investors are encouraged to go paperless and receive Company communications, notices and reports by email. This will ensure efficient communication during COVID-19 while also helping to reduce our costs and environmental footprint.

To easily update your communication preferences, visit: [www.computershare.com.au/easyupdate/lgp](http://www.computershare.com.au/easyupdate/lgp)

